Waverley Pharma announced its wholly-owned Irish Subsidiary – Waverley Pharma Europe Limited, has submitted a Marketing Authorization application through the European Union's De-Centralized Procedure for an anti-cancer generic drug. The product was in-licensed and developed under a collaboration between Waverley Pharma International (a wholly owned Barbados subsidiary of Waverley Pharma Inc.) and Reliance Life Sciences Private Limited ("RLS"). The Marketing Authorization filing is part of an exclusive product supply and development agreement executed on August 30, 2017, under which Waverley Pharma holds all commercial rights in the United States, Canada and the European Union (excluding the United Kingdom, where Waverley Pharma has non-exclusive rights). Regulatory filings in additional jurisdictions are expected to take place in Q2 2018.